{"title":"Metastasiertes Nierenzellkarzinom","authors":"Katharina Arnheim","doi":"10.1055/a-2127-6949","DOIUrl":null,"url":null,"abstract":"Gemäß dem 4-Jahres-Update der Studie CLEAR profitieren Patienten mit fortgeschrittenem Nierenzellkarzinom (RCC) dauerhaft von der Kombinationstherapie mit Lenvatinib plus Pembrolizumab.","PeriodicalId":474444,"journal":{"name":"Onkologische Welt","volume":"59 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Onkologische Welt","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1055/a-2127-6949","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Gemäß dem 4-Jahres-Update der Studie CLEAR profitieren Patienten mit fortgeschrittenem Nierenzellkarzinom (RCC) dauerhaft von der Kombinationstherapie mit Lenvatinib plus Pembrolizumab.